Biogen prices new ALS treatment at $14,230 per vial

Biogen Inc. BIIB has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also known as tofersen, was granted accelerated approval by the U.S. Food and Drug Administration last week. The treatment is administered through a spinal injection. The price tag of $14,230 is the wholesale acquisition cost, the spokesperson said. Biogen stock was down 1.

... Biogen Inc. BIIB has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also known as tofersen, was granted accelerated approval by the U.S. Food and Drug Administration last week. The treatment is administered through a spinal injection. The price tag of $14,230 is the wholesale acquisition cost, the spokesperson said. Biogen stock was down 1.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Ibogaine inspires new compounds to treat addiction, depressionScientists have developed two new drug candidates for potentially treating addiction and depression, modeled on the pharmacology of a traditional African psychedelic plant medicine called ibogaine. At very low doses, these new compounds were able to blunt symptoms of both conditions in mice.
Source: physorg_com - 🏆 388. / 55 Read more »

Asthma sufferers are 36 percent more likely to develop cancerPeople with asthma were found to be 36 percent more likely to develop cancer than people who do not suffer from the chronic respiratory disease, according to research published in the journal Cancer Medicine.
Source: washingtonpost - 🏆 95. / 72 Read more »